Acute Myeloid Leukemia (AML): Symptoms, Subtypes, Diagnosis, and Treatment

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by rapid proliferation of immature myeloid precursors (blasts) in the bone marrow, blood, and occasionally extramedullary sites. It is the most common acute leukemia in adults (median age ~68).

Clinical Presentation

Symptoms reflect bone marrow failure and blast infiltration:

  • Anemia: Fatigue, weakness, exertional dyspnea, pallor
  • Thrombocytopenia: Petechiae, ecchymoses, mucosal bleeding, menorrhagia
  • Neutropenia/Functional immune defect: Fever, infections (bacterial, fungal)
  • Constitutional: Fever, night sweats, weight loss
  • Leukostasis (WBC >100K): Respiratory distress, neurologic changes, priapism — medical emergency
  • Organomegaly: Splenomegaly, hepatomegaly, lymphadenopathy (less prominent than in ALL)

WHO Classification (Simplified)

  • AML with defining genetic abnormalities: t(8;21), inv(16), t(15;17) [APL], KMT2A rearrangements, etc.
  • AML with myelodysplasia-related changes (AML-MRC)
  • Therapy-related AML (t-AML)
  • AML, not otherwise specified (NOS)
  • Myeloid sarcoma (extramedullary)

Molecular profiling (FLT3, NPM1, TP53, ASXL1, etc.) is essential for risk stratification and targeted therapy selection.

Diagnostic Workup

  • CBC with differential, peripheral smear
  • Bone marrow aspirate/biopsy: Morphology, flow cytometry, cytogenetics (karyotype + FISH), molecular panel
  • Coagulation studies (especially for APL)
  • Lumbar puncture if CNS symptoms or high-risk features
  • Cardiac evaluation (anthracycline readiness)
  • Infectious workup (HIV, hepatitis, CMV)

Treatment Paradigm

Fit Patients (Intensive Therapy Eligible)

  • Induction: "7+3" (cytarabine + anthracycline) ± midostaurin (FLT3-mutated) ± gemtuzumab ozogamicin (CD33+)
  • Consolidation: High-dose cytarabine (HiDAC) ± allogeneic transplant (based on risk, donor, MRD)
  • APL (t(15;17)): ATRA + arsenic trioxide ± chemo (non-chemo regimens curative)

Unfit Patients / Older Adults

  • Hypomethylating agents (azacitidine, decitabine) + venetoclax: Standard of care; ~65% CR/CRi
  • Low-dose cytarabine (LDAC) + venetoclax/glasdegib
  • Gilteritinib (FLT3-mutated R/R)
  • Clinical trials strongly preferred

Prognosis

  • Highly variable by age, cytogenetics, molecular markers, MRD status, fitness
  • Younger/favorable risk: 5-yr OS 50–65%
  • Older/adverse risk: 5-yr OS <20%
  • MRD negativity post-consolidation strongly predicts cure

Urgent referral to an academic/tertiary center with leukemia expertise is critical for optimal outcomes.

Blood Disorders - Related Articles